(Total Views: 576)
Posted On: 02/10/2021 8:17:43 AM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
If you were a doctor with a patient, especially pediatric, with mild to moderate disease who might be immune compromised, why wouldn’t you give them a subcutaneous dose of leronlimab as an out patient and monitor them closely. If there isn’t a favorable response after a couple of days, then consider admitting, putting in a PICC, then giving the other drugs. The FDA should have approved CYDY for mild to moderate based on our data and safety record alone as a sensible option. Do the doctors who actually take care of people see the wisdom in this?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)